首页> 外文OA文献 >A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation

【2h】

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation

机译：一项多中心，开放，非对照II期研究，氟达拉滨磷酸，阿糖胞苷和粒细胞集落刺激因子联合治疗复发性和难治性急性髓细胞性白血病和新生难治性贫血并伴有大量母细胞转化

页面导航

摘要
著录项
相似文献
相关主题

摘要

86959

机译：86959

著录项

作者
Jackson G; Taylor P; Smith GM; Marcus R; Smith A; Duncombe A; Chu P; Littlewood TJ; Hutchinson M; Mehta AB; Johnson SA; Carey P; Mackie MJ; Ganly PS; Turner GE; Deane M; Schey S; Brookes J; Tollerfield SM; Wilson MP;
展开▼
作者单位

展开▼
年度 2001
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II study of FLAGM (fludarabine plus high-dose cytarabine plus granulocyte colony-stimulating factor plus mitoxantrone) for relapsed or refractory acute myeloid leukemia [J] . Hatsumi Nahoko, Miyawaki Shuichi, Yamauchi Takahiro, International journal of hematology . 2019,第4期

机译：Flagm的II期研究（Fludarabine加上高剂量的溶血性刺激因子加mitoxantrone）用于复发或难治性急性髓性白血病
2. Efficacy and Safety of C-CAG Regimen (cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine and aclarubicin) in Patients with Refractory/Relapsed Acute Myeloid Leukemia: A Phase 2, Single Center, Single Arm Study [J] . Wang Hua, Lu Yue Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：C-CAG方案（CLADRIBINE与粒细胞菌落刺激因子，低剂量红细胞和AClarubicin组合）的疗效和安全性在难治性/复发急性髓性白血病患者中：2，单中心，单臂研究
3. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study [J] . Hua Wang, Liang Wang, Chun Li, The oncologist . 2020,第11期

机译：用粒细胞菌落刺激因子，糖碱和难治性/复发急性髓鞘白血病中的粒细胞刺激因子，溶细胞素和Aclarubicin方案：II期多中心研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Chidamide decitabine cytarabine aclarubicin and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm phase 1/2 study [O] . Lixin Wang, Jianmin Luo, Guofeng Chen, 2020

机译：茜酰胺去甲脒糖胺血清细胞菌落刺激因子（CDCAG）患者复发/难治性急性髓性白血病：单臂第1/2研究
6. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation [O] . Jackson G, Taylor P, Smith G M, 2001

机译：一项多中心，开放，非对照II期研究，氟达拉滨磷酸，阿糖胞苷和粒细胞集落刺激因子联合治疗复发性和难治性急性髓细胞性白血病和新生难治性贫血并伴有大量母细胞转化

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation

摘要

著录项

相似文献

相关主题

期刊订阅